This is an automatically translated article.
For those who often experience seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria, the name Desacure must not be too strange anymore. So what is Destacure and how should it be used? Please follow the details in the following article.
1. What is Destacure? Indications for the use of Destacure
According to the manufacturer's information, every 5ml of Destacure medicine syrup contains 2.5mg of the active ingredient Desloratadine and excipients: Sucrose, Sodium benzoate, Disodium edetat, Bronopol, 70% sorbitol solution, Propylene Glycol, Anhydrous citric acid, Sunset color Yellow Supra, Ess. Sweet Orange No.1, Aspartam, Purified Water.
Destacure is manufactured with a number of indications such as:
Seasonal allergic rhinitis: Desacure is indicated for the rapid relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis: Administration of Desacure rapidly relieves symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic idiopathic urticaria: Destacure has been shown to provide rapid relief of pruritus symptoms and reduction in the number and size of rashes in patients with chronic idiopathic urticaria 6 months of age and older.
2. Notes when using Destacure
Depending on the subject and age, Destacure is used in different doses. Accordingly, patients should use Age-appropriate Destacure by measuring with a dropper or syringe to get from 2ml to 2.5ml (1/2 teaspoon).
For adults and children over 12 years of age, the recommended dose of Desacure is 2 full teaspoons (5mg in 10ml) once daily. Children 6 to 11 years old should take 1 full teaspoon (2.5mg in 5ml) once a day. Children 12 months to 5 years old is 1⁄2 teaspoons (1.25mg in 2.5ml) once daily. Children 6 months to 11 months of age is 2ml (1.0mg) once daily. In particular, Destacure is contraindicated in patients with hypersensitivity to any component of the drug or hypersensitivity to loratadine. When there are reactions due to hypersensitivity to the ingredients of the drug such as rash, itching, urticaria, edema, difficulty breathing, the patient should stop desloratadine and replace with another treatment.
In the event of an overdose, standard measures should be taken to remove the unabsorbed active ingredient from the body. Accordingly, it is necessary to have symptomatic and supportive treatment measures.
Based on different dose clinical trials in adults and adolescents with doses up to 45 mg of Desloratadine (9 times the usual dose) no clinically relevant effects were observed. .
Desloratadine cannot be removed by hemodialysis, but it is not known whether it is eliminated by peritoneal dialysis.
3. Undesirable effects of the drug Destacure
Desacure side effects are not common and vary from person to person. However, there are some common conditions when using this drug such as diarrhea, insomnia, fatigue, dry mouth and headache. Other very rare side effects reported during follow-up such as hallucinations, dizziness, somnolence, insomnia, neuromotor hyperactivity, seizures, tachycardia, palpitations, elevation liver enzymes, increased bilirubin, hepatitis. You should tell your doctor if you have any side effects related to taking the medicine.
4. Interactions with other drugs
Cytochrome P450 3A4 Inhibitors: In controlled clinical studies, oral desloratadine in combination with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3-hydroxydesloratadine, but no effects were observed. There were no clinical manifestations associated with interactions with desloratadine in clinical studies. Fluoxetine: In controlled clinical studies, oral desloratadine was shown in combination with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulting in progressively increased plasma concentrations of desloratadine and 3-hydroxydesloratadine . However, no clinically relevant interactions with desloratadine were observed in clinical studies. Cimetidine: In controlled clinical studies, oral desloratadine was shown in combination with cimetidine, a histamine H2-receptor antagonist, resulting in progressively increased plasma concentrations of desloratadine and 3-hydroxydesloratadine. However, no clinically relevant interactions with desloratadine were observed in clinical studies.
5. Some extensive information on the pharmacology of Destacure
5.1. Pharmacodynamics Desloratadine is a selective, long-acting, non-sedating, peripheral H1-receptor antagonist of histamine. After oral administration, desloratamine selectively inhibits peripheral histamine H1 receptors, because the drug does not enter the central nervous system.
In in vitro studies, Desloratadine has been shown to have antiallergic effects, including inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from mast cells/basophil cells, as well as inhibiting the expression of adhesion molecules such as P-selectin on endothelial cells. The clinical effect of treatment is still being monitored.
5.2. Pharmacokinetics Desloratadine plasma concentrations can be found 30 minutes after oral administration in adults and adolescents. Desloratadine is well absorbed, reaching maximum plasma concentrations approximately 3 hours after oral administration, with a terminal elimination half-life of approximately 27 hours. The accumulation of desioratadine is consistent with the half-life (approximately 27 hours) and once-daily dosing. The bioavailability of desloratadine is dose proportional in the range of 5 - 20 mg.
The mean half-life of desloratadine is 27 hours. Peak Cmax and AUC values increase dose proportionally after a single dose between 5 and 20 mg. The extent of accumulation after 14 days of dosing was consistent with the half-life and dose frequency. A balance of excretion study in humans showed that approximately 87% of a dose of 14C-Desloratadine was equally distributed in the urine and faeces. Analysis of 3-hydroxydesloratadine in plasma showed similar values of Tmax and half-life compared with Desloratadine.
In summary, Desacure is indicated for the treatment of seasonal, perennial allergic rhinitis and chronic urticaria. However, the use of the drug can cause some side effects. Therefore, patients should carefully read the instructions for use or consult a doctor or pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
